<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301716</url>
  </required_header>
  <id_info>
    <org_study_id>PIM4946g</org_study_id>
    <secondary_id>GO01336</secondary_id>
    <nct_id>NCT01301716</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors</brief_title>
  <official_title>A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety,
      tolerability, and pharmacokinetics of GDC-0980 administered with either paclitaxel and
      carboplatin (with or without bevacizumab) or pemetrexed and cisplatin to patients with
      locally advanced or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days after last dose of study treatment or initiation of new anti-cancer therapy, whichever comes first</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 21 days from Last Patient In (LPI) in Stage 1 of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature of adverse events</measure>
    <time_frame>Up to 30 days after last dose of study treatment or initiation of new anti-cancer therapy, whichever comes first</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature of dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 21 days from Last Patient In (LPI) in Stage 1 of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>Up to 30 days after last dose of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total exposure</measure>
    <time_frame>Up to 32 months or early study discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration</measure>
    <time_frame>Up to 32 months or early study discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed plasma concentration</measure>
    <time_frame>Up to 32 months or early study discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life</measure>
    <time_frame>Up to 32 months or early study discontinuation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Solid Cancers</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0980</intervention_name>
    <description>Oral escalating dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>intravenous repeating dose</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>intravenous repeating dose</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically documented, incurable, locally advanced, or metastatic
             solid malignancy

          -  Adequate hematologic and end organ function

          -  For female patients of childbearing potential and male patients with partners of
             childbearing potential, agreement to use an effective form of contraception and to
             continue its use for the duration of the study

          -  Measurable disease per RECIST (Response Evaluable Criteria in Solid Tumors), with the
             exception of prostate cancer (two rising PSA Levels that meet the criteria of
             progression per PSA Working Group) and ovarian cancer (two rising CA-125 levels
             greater than the ULN)

        Exclusion Criteria:

          -  Current dyspnea at rest due to complications of advanced malignancy, or other
             conditions requiring continuous supplemental oxygen

          -  Uncontrolled hypomagnesemia or hypokalemia

          -  History of Grade &gt;= 3 fasting hyperglycemia

          -  Any condition requiring full-dose anticoagulants

          -  Known HIV infection

          -  Known untreated or active central nervous system (CNS) metastases

          -  Pregnancy, lactation, or breastfeeding

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to the first dose of study treatment or anticipation of need for major surgical
             procedure during the course of the study

          -  For Arm B: Conditions that preclude the use of bevacizumab

          -  For Arm C: Conditions that preclude the use of pemetrexed or cisplatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>February 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

